11β-HSD1 Inhibition by RL-118 Promotes Autophagy and Correlates with Reduced Oxidative Stress and Inflammation, Enhancing Cognitive Performance in SAMP8 Mouse Model
- 183 Downloads
Elevated glucocorticoid (GC) exposure is widely accepted as a key factor in the age-related cognitive decline in rodents and humans. 11β-HSD1 is a key enzyme in the GCs pathway, catalyzing the conversion of 11β-dehydrocorticosterone to corticosterone in mice, with possible implications in neurodegenerative processes and cognitive impairment. Here, we determined the effect of a new 11β-HSD1 inhibitor, RL-118, administered to 12-month-old senescence-accelerated mouse-prone 8 (SAMP8) mice with neuropathological AD-like hallmarks and widely used as a rodent model of cognitive dysfunction. Behavioral tests (open field and object location) and neurodegeneration molecular markers were studied. After RL-118 treatment, increased locomotor activity and cognitive performance were found. Likewise, we found changes in hippocampal autophagy markers such as Beclin1, LC3B, AMPKα, and mTOR, indicating a progression in the autophagy process. In line with autophagy increase, a diminution in phosphorylated tau species (Ser 396 and Ser 404) jointly with an increase in ADAM10 and sAPPα indicated that an improvement in removing the abnormal proteins by autophagy might be implicated in the neuroprotective role of the 11β-HSD1 inhibitor. In addition, gene expression of oxidative stress (OS) and inflammatory markers, such as Hmox1, Aldh2, Il-1β, and Ccl3, were reduced in old treated mice in comparison to that of the control group. Consistent with this, we further demonstrate a significant correlation with autophagy markers and cognitive improvement and significant inverse correlation with autophagy, OS, and neuroinflammation markers. We concluded that inhibition of 11β-HSD1 by RL-118 prevented neurodegenerative processes and cognitive decline, acting on autophagy process, being an additional neuroprotective mechanism not described previously.
KeywordsBehavior Learning Cognition Inflammation Hippocampus Oxidative stress Neurodegeneration APP Tau Aging
We thank Maggie Brunner, M.A., for revising the language and style of the manuscript.
Participated in research design: Puigoriol-Illamola, Griñan-Ferré., Pallàs.
Conducted experiments: Puigoriol-Illamola, Griñan-Ferré, Vasilopoulou, Leiva.
Contributed new reagents or analytic tools: Leiva, Vazquez.
Performed data analysis: Puigoriol-Illamola, Griñan-Ferré.
Wrote or contributed to the writing of the manuscript: Puigoriol-Illamola, Griñán-Ferré, Leiva, Vazquez, Pallàs
This study was supported by the Ministerio de Economía y Competitividad of Spain SAF2016-33307 and SAF2014-57094R. D.P-I. and R.L. thank the Spanish Ministerio de Educación Cultura y Deporte for a PhD Grant (FPU program). Authors belong to 2017SGR106 from AGAUR, Catalonia.
- 6.Yu WH, Kumar A, Peterhoff C, Shapiro Kulnane L, Uchiyama Y, Lamb BT, Cuervo AM, Nixon RA (2004) Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer’s disease. Int J Biochem Cell Biol 36:2531–2540CrossRefPubMedGoogle Scholar
- 9.Höhn A, Weber D, Jung T, Ott C, Hugo M, Kochlik B, Kehm R, König J et al (2016) Happily (n)ever after: aging in the context of oxidative stress, proteostasis loss and celular senescence. Redox Biol S2213-2317(16):30351–30352Google Scholar
- 17.Holmes MC, Carter RN, Noble J, Chitnis S, Dutia A, Paterson JM, Yau JLW (2010) 11β-Hydroxysteroid dehydrogenase type 1 expression is increased in the aged mouse hippocampus and parietal cortex and causes memory impairments. J Neurosci 30(20):6916–6920. https://doi.org/10.1523/JNEUROSCI.0731-10.2010 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Yau JL, Noble J, Kenyon CJ, Hibberd C, Kotelevtsev Y, Mullins JJ, Seckl JR (2001) Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad Sci U S A 98:4716–4721CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Leiva R, Griñán-Ferré C, Seira C, Valverde E, McBride A, Binnie M, Pérez B, Luque FJ et al (2017) Design, synthesis and in vivo study of novel pyrrolidine-based 11β-HSD1 inhibitors for age-related cognitive dysfunction. Eur J Med Chem 139:412–428. https://doi.org/10.1016/j.ejmech.2017.08.003 CrossRefPubMedGoogle Scholar
- 27.Sooy K, Webster SP, Noble J, Binnie M, Walker BR, Seckl JR, Yau JLW (2010) Partial deficiency or short-term inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves cognitive function in ageing mice. J Neurosci 30(41):13867–13872. https://doi.org/10.1523/JNEUROSCI.2783-10.2010 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Mah L, Binns MA, Steffens DC, Alzheimer’s Disease Neuroimaging Initiative (2015) Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am J Geriatr Psychiatry 23:466–476. https://doi.org/10.1016/j.jagp.2014.10.005 CrossRefPubMedGoogle Scholar
- 29.Ramakers IHGB, Verhey FRJ, Scheltens P, Hampel H, Soininen H, Aalten P, Rikkert MO, Verbeek MM et al (2013) Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med 43:911–920. https://doi.org/10.1017/S0033291712001870 CrossRefPubMedGoogle Scholar